Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant PD-L1 Blockade Combined With Anlotinib to Enable Nephron-Sparing Surgery in Patients With High-Complexity Locally Advanced Clear Cell Renal Cell Carcinoma

NCT07602101 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT07602101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07602101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant PD-L1 Blockade Combined With Anlotinib to Enable Nephron-Sparing Surgery in Patients With High-Complexity Locally Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
December 31, 2028
Enrollment
33 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma